Empowered Funds LLC acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 18,587 shares of the company's stock, valued at approximately $379,000.
Several other large investors also recently made changes to their positions in the business. CWM LLC lifted its stake in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after buying an additional 654 shares in the last quarter. Creative Planning lifted its stake in Denali Therapeutics by 40.0% during the third quarter. Creative Planning now owns 60,254 shares of the company's stock valued at $1,755,000 after buying an additional 17,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after buying an additional 920 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Denali Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,535 shares of the company's stock valued at $802,000 after buying an additional 10,782 shares in the last quarter. Finally, Integrated Advisors Network LLC purchased a new stake in Denali Therapeutics during the third quarter valued at about $283,000. Institutional investors own 92.92% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target for the company. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. Finally, HC Wainwright cut their price objective on shares of Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $37.42.
Check Out Our Latest Research Report on Denali Therapeutics
Insider Transactions at Denali Therapeutics
In other news, insider Carole Ho sold 12,255 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,940 shares of company stock worth $973,442. Insiders own 7.90% of the company's stock.
Denali Therapeutics Stock Down 3.9 %
DNLI stock traded down $0.84 during midday trading on Friday, hitting $20.75. 831,159 shares of the company traded hands, compared to its average volume of 793,528. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33. The business has a 50 day simple moving average of $21.62 and a 200-day simple moving average of $24.67. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -7.52 and a beta of 1.43.
About Denali Therapeutics
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Further Reading
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
